Tempus AI (NASDAQ:TEM) Price Target Raised to $95.00

Tempus AI (NASDAQ:TEM) had its price objective hoisted by Canaccord Genuity Group from $80.00 to $95.00 in a research note released on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also recently weighed in on TEM. Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $56.00 to $76.00 in a research report on Tuesday, September 1st. Stifel Nicolaus dropped their target price on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. TD Cowen reissued a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, UBS Group began coverage on Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price target on the stock. Eleven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $72.37.

Tempus AI Stock Up 0.1%

Shares of TEM opened at $68.32 on Monday. The firm has a market cap of $12.33 billion, a P/E ratio of -47.44 and a beta of 3.54. Tempus AI has a 12-month low of $40.77 and a 12-month high of $97.25. The company’s 50-day moving average price is $67.31 and its 200 day moving average price is $56.23. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. Tempus AI’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.22) earnings per share. On average, sell-side analysts forecast that Tempus AI will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Tempus AI

In related news, CEO Ryan Fukushima sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total transaction of $49,000.00. Following the sale, the chief executive officer directly owned 15,874 shares of the company’s stock, valued at $1,111,180. This represents a 4.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the sale, the chief executive officer owned 100,000 shares in the company, valued at approximately $7,747,000. This trade represents a 71.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,280,965 shares of company stock valued at $80,397,564. Corporate insiders own 24.26% of the company’s stock.

Hedge Funds Weigh In On Tempus AI

Institutional investors have recently modified their holdings of the business. Arkadios Wealth Advisors lifted its holdings in Tempus AI by 9.6% during the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock worth $224,000 after buying an additional 435 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Tempus AI by 54.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock valued at $101,000 after acquiring an additional 436 shares during the last quarter. EMC Capital Management purchased a new position in shares of Tempus AI in the 2nd quarter valued at about $29,000. Ulland Investment Advisors LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $41,000. Finally, NewEdge Advisors LLC raised its position in shares of Tempus AI by 1.3% during the 1st quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock worth $1,944,000 after acquiring an additional 536 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.